Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Editas Medicine ( (EDIT) ) just unveiled an announcement.
On September 2, 2025, Editas Medicine announced the nomination of EDIT-401 as its lead in vivo development candidate. EDIT-401 is designed to reduce LDL cholesterol levels by editing the LDLR gene, showing promising preclinical results with a significant reduction in LDL-C levels and increased LDLR protein expression. The company plans to focus on advancing EDIT-401 to human proof-of-concept and aims to submit an IND or CTA by mid-2026. Additionally, Editas confirmed its financial stability, projecting its cash runway to extend into the second quarter of 2027.
The most recent analyst rating on (EDIT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Editas Medicine stock, see the EDIT Stock Forecast page.
Spark’s Take on EDIT Stock
According to Spark, TipRanks’ AI Analyst, EDIT is a Neutral.
Editas Medicine’s overall stock score reflects a challenging financial position with persistent losses and negative cash flow, offset by a strong cash reserve. The technical analysis indicates a bullish trend, but caution is warranted due to potential overbought conditions. Promising corporate events in gene editing provide a positive outlook, but the valuation remains a concern due to negative earnings.
To see Spark’s full report on EDIT stock, click here.
More about Editas Medicine
Editas Medicine is a biotechnology company focused on developing gene editing therapies. The company is primarily engaged in creating innovative treatments for genetic disorders, with a significant focus on in vivo gene editing solutions.
Average Trading Volume: 2,492,468
Technical Sentiment Signal: Sell
Current Market Cap: $231.1M
Find detailed analytics on EDIT stock on TipRanks’ Stock Analysis page.